Founded in 2019 by Kevin E. Healy and Samuel T. Wall, Organos is a software company based in Moraga, California, dedicated to pioneering drug discovery for cardiac health. The company's core mission is to address the stagnation in new cardiac therapies by providing predictive, human-relevant preclinical models of the human heart. Organos offers an advanced analysis of action potential and calcium transient dynamics in cardiac microphysiological systems (MPS) to predict arrhythmia, utilizing a silico framework to translate measurements into mechanisms of action and estimate IC50 values of ion channels.

Notable figures affiliated with Organos include its founders, Kevin E. Healy and Samuel T. Wall, who bring extensive expertise in bioengineering and computational biology. The company has attracted significant attention from investors interested in innovative healthcare solutions. Key achievements include the development of a robust platform for high-throughput screening (HTS) assays, which has the potential to revolutionize cardiac drug discovery by making large compound libraries more accessible for testing. Organos' impact lies in its potential to significantly accelerate the development of effective cardiac therapies, addressing a critical need in healthcare.